Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HEPA 
Hepion Pharmaceuticals Inc (HEPA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/04/2025: HEPA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.77M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta 1.52 | 52 Weeks Range 0.03 - 44.50 | Updated Date 09/4/2025 |
52 Weeks Range 0.03 - 44.50 | Updated Date 09/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -45.85 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate - | Actual -0.09 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -98.47% | Return on Equity (TTM) -368.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -133172 | Price to Sales(TTM) - |
Enterprise Value -133172 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 10976300 | Shares Floating 11620317 |
Shares Outstanding 10976300 | Shares Floating 11620317 | ||
Percent Insiders - | Percent Institutions 0.2 |
Upturn AI SWOT
Hepion Pharmaceuticals Inc
Company Overview
History and Background
Hepion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for liver disease. Founded in 2013, it is dedicated to advancing treatments for non-alcoholic steatohepatitis (NASH) and other liver-related conditions.
Core Business Areas
- Drug Development: Development of Rencofilstat, a novel oral therapy that targets NASH by inhibiting cyclophilin pathways.
Leadership and Structure
The leadership team includes Robert Foster (CEO) and other executives with expertise in drug development and commercialization. The company has a typical organizational structure for a biotechnology firm, with departments focused on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Rencofilstat: Rencofilstat is Hepion's leading drug candidate designed to treat NASH. It's currently in clinical trials. Market share data is not yet available as the drug is not yet commercialized. Competitors include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The liver disease treatment market, particularly for NASH, is rapidly growing due to increasing prevalence of obesity and diabetes. There's a high unmet need for effective therapies.
Positioning
Hepion is positioned as an innovator in the NASH treatment space with Rencofilstat, which has a novel mechanism of action. Their competitive advantage lies in this unique target and potentially favorable safety profile.
Total Addressable Market (TAM)
The global NASH market is expected to reach USD 50 billion by 2030. Hepion aims to capture a significant portion of this market with Rencofilstat, assuming successful clinical trials and regulatory approval. Their positioning rests on their drug's efficacy and safety profile within the NASH patient population.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for Rencofilstat
- Experienced leadership team
- Focus on high-unmet need in NASH treatment
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trial outcomes
Opportunities
- Positive clinical trial results for Rencofilstat
- Partnerships with larger pharmaceutical companies
- Expansion into other liver disease indications
Threats
- Failure to achieve positive clinical trial results
- Competition from other companies developing NASH treatments
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
Competitive Landscape
Hepion is a smaller player in the NASH market compared to larger pharmaceutical companies like Gilead. Its competitive advantage is the unique mechanism of Rencofilstat, but it faces the risk of larger companies with more resources developing competing therapies. MDGL may have the first approved NASH drug with resmetiromie.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical trial advancements rather than revenue generation. Growth is dependent on the progression of Rencofilstat through clinical trials.
Future Projections: Future growth hinges on successful clinical trials, regulatory approval, and eventual commercialization of Rencofilstat. Analyst estimates vary based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Rencofilstat and presentations at scientific conferences to highlight its potential.
Summary
Hepion Pharmaceuticals is a high-risk, high-reward clinical-stage company focused on NASH. Its key strength is Rencofilstat's novel approach, but it faces financial and regulatory hurdles. Positive clinical trial results are critical for its future success, while potential competition remains a significant threat. The lack of partnerships also needs to be looked out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hepion Pharmaceuticals Inc. SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is an estimate and may not be precise. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hepion Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Morristown, NJ, United States | ||
IPO Launch date 2014-02-11 | Interim CEO & Director Dr. Kaouthar Lbiati M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://hepionpharma.com |
Full time employees - | Website https://hepionpharma.com | ||
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.